Ascendis Pharma A/S (ASND) fair value analysis
Nasdaq · Updated 2026-10-19
ASND price how computed
Valuation status
Reports in EURASND reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for ASND until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $227.31
- Sector
- Healthcare
- 12-month range
- $196.01–$277.18
- Market cap
- $15B
- From 52-week high
- -18.0%
- Shares outstanding
- 65.8M
- Rank in Healthcare by quality score
- #16 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
Ascendis Pharma A/S is a biopharmaceutical company that develops and commercializes medications using its TransCon technology platform to treat endocrine and other serious diseases. The company operates internationally with operations in multiple countries including Denmark, where it is headquartered, and the United States.
ASND currently ranks #16 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $15B
- Revenue (TTM)
- EUR 1.05B
- Net margin
- 71.7%
- EPS (TTM)
- EUR 2.01
- Gross margin
- 90.6%
- Debt / equity
- 0.31
- Revenue growth (3-yr avg)
- 206.0%
- Shares outstanding
- 65.8M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 40 · neutral
- 50-day average
- $244.15
- 200-day average
- $236.09
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-11
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▲ beat (+321.8%)
2026-03 ▼ miss (-37.2%)
2025-12 ▼ miss (-129.2%)
2025-09 ▼ miss (-733.3%)
2025-06 ▲ beat (+34.5%)
2025-03 ▼ miss (-4.6%)
2024-12 ▲ beat (+45.3%)
2024-09 ▼ miss (-17.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 20 buy · 0 hold · 0 sell (20 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $307
- Target vs last price
- +35.1%
What our data shows for ASND
- Shares are trading in the middle of their 12-month price range of $196.01–$277.18.
- The 14-day relative strength index sits at a neutral 40.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ASND's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ASND news
TickrTrends' derived news-sentiment signal for ASND is currently leaning positive, computed from recent coverage.
- Ascendis Pharma (ASND) Receives Positive CHMP Opinion for TransCon CNP in Europe (gurufocus.com, 2026-10-16)
- Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children (manilatimes.net, 2026-10-16)
- ASND Assumed by UBS -- Price Target Lowered to $269 (gurufocus.com, 2026-10-15)
More ASND news
- Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026 (manilatimes.net, 2026-10-06)
- Ascendis Pharma (ASND) Authorizes $400M Share Buyback (insidermonkey.com, 2026-09-21)
- Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript (seekingalpha.com, 2026-09-15)
What people are saying
Follow the ASND conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — # ASND - TickrTrends Summary TickrTrends' derived indicators for ASND show a shift in trend momentum this week, with the 50/200-day trend state moving from uptrend to mixed, suggesting reduced directional conviction in the healthcare sector name. The full valuation assessment remains pending, indicating that complete pricing analysis is still being compiled. This change in trend state reflects altered momentum dynamics compared to the prior week's readings.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ASND stock undervalued?
ASND reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for ASND until same-currency inputs are available.
What is ASND's TickrTrends verdict?
ASND is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does ASND compare to other Healthcare stocks?
ASND ranks #16 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ASND overbought or oversold?
ASND's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ASND report earnings next?
ASND's next earnings report is scheduled for 2026-11-11, per the published earnings calendar.
Does ASND usually beat earnings estimates?
Over its last 8 reported quarters ASND beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ASND?
Of 20 analysts covering ASND, 20 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $307 (+35.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.